Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.
An interdisciplinary gathering at the 2025 virtual conference of the Society for Digital Mental Health heard presentations and panel discussions on digital therapeutics, along with reports of studies on the technology and outcomes by student and young researchers.